Drug Database
IN

insulin human + insulin isophane (Insugen 30/70)

✓ Approved

Bayer AG · INSR · 重组蛋白

什么是 insulin human + insulin isophane?

insulin human + insulin isophane 是一种重组蛋白,由Bayer AG研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Insugen 30/70
公司Bayer AG
药物类别重组蛋白
分子靶点INSR
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

insulin human + insulin isophane 作用于 1 个分子靶点:

INSRinsulin receptor (CD220, HHF5)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

insulin human + insulin isophane 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersType 1 diabetes mellitus✓ Approved
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

相关研究文献

PubMedDiabetes, obesity & metabolism2026-11-19

Insulin Secretion Modelling to Characterize Post-Bariatric Hypoglycaemia After Roux-en-Y Gastric Bypass.

Mohammadi-Asl E E, El Fathi A A, Pei L L, Saeed H H et al.

Roux-en-Y Gastric Bypass (RYGB) is an effective treatment for obesity and Type 2 diabetes. Some individuals develop postprandial hypoglycaemia, termed post-bariatric hypoglycaemia (PBH). PBH is associated with marked postprandial increases in incretin and insulin levels. This study investigates how insulin secretion differs between post-RYGB patients with and without hypoglycaemia by identifying key secretion parameters. Insulin secretion was modelled using plasma glucose, insulin and C-peptide concentration data obtained from mixed meal tolerance test in three cohorts: healthy individuals without a history of upper gastrointestinal surgery (controls, n = 11), post-RYGB individuals without hypoglycaemia (RYGB-non-hypo, n = 18) and post-RYGB individuals with hypoglycaemia (RYGB-PBH, n = 20). Meal-driven insulin secretion differed across groups (p = 0.008) and was significantly higher in RYGB-PBH than controls (0.23 vs. 0.14 pmol/mg, p = 0.006), but not in RYGB-non-hypo (0.22, p = 0.071). Glucose-driven insulin secretion decreased in RYGB-non-hypo (0.04 vs. 0.07 pmol/kg/min per mg/dL, p = 0.005) but did not differ from controls in RYGB-PBH (0.08, p = 0.948), differing significantly between the two post-RYGB groups (p < 0.001). Meal absorption was significantly faster in both post-RYGB groups (9.08 and 8.44 vs. 11.48 min, both p < 0.001). Models fit plasma insulin and C-peptide well (mean joint nRMSE: 0.60-0.92 across groups). Parameters were estimated with good precision (CV < 100%). Insulin secretion dynamics differ between post-RYGB patients with and without hypoglycaemia. Both groups showed faster meal absorption and a shift towards higher meal-driven secretion, significant only in RYGB-PBH, but only those without hypoglycaemia showed a reduction in glucose-driven secretion. This PBH model can support in silico development of glucagon-based interventions.

PMID 43053530
阅读全文 →
PubMedWorld journal of psychiatry2026-11-19

Correction to: KAT7/HMGN1 signaling epigenetically induces tyrosine phosphorylation-regulated kinase 1A expression to ameliorate insulin resistance in Alzheimer's disease.

Lu Qun-Shan QS, Ma Lin L, Jiang Wen-Jing WJ, Wang Xing-Bang XB et al.

[This corrects the article DOI: 10.5498/wjp.v14.i3.445.][This corrects the article on p. 445 in vol. 14, PMID: 38617985.].

PMID 43053753
阅读全文 →
PubMedNature2026-11-19

A glucose-powered artificial neuroimmune axis for metabolic control.

Xiu Weijun W, Wang Qian Q, Wan Ling L, Liang Zhuoming Z et al.

Metabolic disorders such as diabetes mellitus are global health crises driven by metabolic imbalance, chronic inflammation and dysfunction of the neuroimmune axis1-3. Electroceuticals targeting the autonomic nervous system have shown anti-inflammatory effects, yet existing systems lack the metabolic interoceptive feedback to fully restore immune-metabolic homeostasis4-9. Here we report an artificial neuroimmune axis (NeuroAxis) as a closed-loop immunomodulatory therapy for treating metabolic diseases. Analogous to its biological counterpart, NeuroAxis is solely powered by endogenous glucose, operating without batteries or wireless power transfer. It emulates the vagal reflex through closed-loop neuromodulation with metabolic interoceptive feedback. In a rat model of type 1 diabetes, NeuroAxis promotes the recovery of insulin-producing pancreatic β-cells and reduces inflammatory immune responses; in a rat model of type 2 diabetes, it drives macrophage remodelling and reduces systemic chronic inflammation. In both models, NeuroAxis restores glucose tolerance, improves insulin sensitivity and normalizes glycaemic control, with therapeutic effects persisting after treatment cessation. Our artificial neuroimmune axis promotes substantial advances in treating metabolic disorders and represents a general approach for autonomously regulating interorgan communication, central to homeostasis and pathophysiology.

PMID 43052470
阅读全文 →
PubMedBMC cardiovascular disorders2026-11-19

The comparative performance of insulin resistance and visceral adiposity composites over traditional indices for cardiometabolic multimorbidity risk stratification: a multi-dimensional analysis of 16 markers and 5 pathophysiological pathways in the CHARLS cohort.

Zhang Lisha L, Zhang Yan Y, Deng Fuxue F, Jiang Wei W et al.

To compare the associations and incremental discriminatory ability of 16 alternative metabolic markers with incident cardiometabolic multimorbidity (CMM) and explore potential mediating pathways. Using the CHARLS cohort (n = 7,646), we evaluated 16 markers. Primary analyses comprised Cox regression, competing-risk models, and ROC/IDI/NRI assessments of incremental discrimination. XGBoost, qgcomp, and SEM served as secondary/exploratory analyses of feature importance, mixture effects, and mediation pathways. During follow-up, 633 participants developed CMM. All markers were significantly associated with CMM in quartile analyses; CVAI showed the strongest association (Q4 vs. Q1 HR: 5.15, 95% CI: 3.52-7.54). TyG-WC provided the greatest incremental improvement in discrimination (IDI = 0.026, NRI = 0.255, P < 0.001). Composite insulin resistance (IR) and atherogenic lipid indices accounted for 87.8% of the joint risk weight. SEM revealed a suppression pattern: biochemical IR statistically accounted for the association between structural (anthropometric) adiposity and CMM (indirect effect: 0.34, P < 0.001; mediation proportion: 121.9%, reflecting inconsistent mediation rather than complete mediation), while the direct effect of structural adiposity was negative and non-significant (P > 0.05). Integrating biochemical and anthropometric markers (particularly TyG-WC) improves CMM risk stratification, although the incremental gains were modest and require external validation before clinical implementation. The association between structural adiposity and CMM was statistically accounted for by biochemical IR; in exploratory SEM analyses, structural obesity without metabolic dysfunction was not independently associated with CMM in this cohort. Whether this reflects a metabolically healthy phenotype warrants further study. Not applicable.

PMID 43052776
阅读全文 →
PubMedJournal of ovarian research2026-11-19

Beyond a one-size-fits-all prescription: shared and differential anti-inflammatory responses to exercise modalities in polycystic ovary syndrome.

Wang Junli J, Li Junhua J, Li Chaoyong C, Zou Xugui X

Polycystic ovary syndrome (PCOS) is a multisystem disorder in which chronic low-grade inflammation intersects with metabolic, reproductive, and psychological dysfunction, yet exercise guidance remains largely generic. This narrative review examines whether different exercise stimuli are associated with different patterns of anti-inflammatory adaptation in PCOS. Four intervention categories are considered: high-intensity interval training (HIIT), characterized by repeated high-intensity metabolic perturbations; resistance training (RT), characterized by progressive mechanical loading; endurance training (ET), characterized by sustained aerobic and vascular shear-stress exposure; and mind-body training (MBT), a heterogeneous complementary category that includes yoga, controlled breathing, meditation, and mindful movement. These categories are operational rather than biologically discrete. Mitochondrial remodeling, improved insulin signaling, redox adaptation, myokine and adipokine changes, vascular responses, and immune modulation occur across several modalities, although their relative magnitude, timing, and tissue emphasis may differ. Direct head-to-head mechanistic comparisons in women with PCOS remain scarce; therefore, assignments of AMPK-PGC-1α emphasis to HIIT, mTOR-centered mechanotransduction to RT, eNOS-related vascular adaptation to ET, and autonomic-HPA regulation to MBT should be interpreted as hypothesis-generating rather than modality-exclusive. Current evidence supports benefits of several exercise approaches for fitness, insulin sensitivity, body composition, vascular function, psychological health, and selected inflammatory markers, but does not establish phenotype-specific superiority. Future comparative trials should combine standardized exercise reporting, phenotype stratification, acute and resting biomarker sampling, and tissue-level or multi-omic endpoints to determine whether clinically useful response profiles can support more individualized exercise prescription in PCOS.

PMID 43053185
阅读全文 →
PubMedBMC endocrine disorders2026-11-19

One-hour plasma glucose identifies metabolic subgroups in individuals with HbA1c-defined prediabetes and normal fasting and 2-hour glucose.

Ouyang Ling L, Nie Qianwen Q, Huang Youyuan Y, Qiu Xue X et al.

This study evaluated whether 1-hour postload glucose (1-h PG) identifies distinct metabolic subgroups with differing OGTT-derived β-cell function indices among Chinese adults with HbA1c-defined prediabetes and normal fasting and 2-hour glucose. This cross-sectional study included 8,537 Chinese adults undergoing 75-g OGTT and HbA1c testing. Participants were stratified into four glycemic phenotypes based on HbA1c (≥5.7%) and OGTT criteria. Within the HbA1c+/OGTT- subgroup (n=922), individuals were further classified by 1-h PG (cutoff 8.6 mmol/L). β-cell function was assessed using the disposition index (DI). Linear mixed-effects models analyzed glucose and insulin dynamics. Among 3,800 individuals with prediabetes, 24.3% exhibited isolated HbA1c elevation (HbA1c+/OGTT-). Within this discordant subgroup, 51.8% had elevated 1-h PG (≥8.6 mmol/L). The 1-h PG+ subgroup demonstrated lower β-cell function (DI = 40.47), delayed glucose peaks (60 min), impaired early-phase insulin secretion, and greater overall glycaemic exposure, whereas the 1-h PG- subgroup exhibited preserved or enhanced β-cell function (DI = 85.19 vs. 75.56 in NGT, P < 0.001). Multivariable linear regression analysis demonstrated that 1-h PG remained significantly associated with β-cell function after adjustment for age, sex, and HbA1c. Among individuals with HbA1c-defined prediabetes and normal Fasting and 2-Hour Glucose, 1-hour plasma glucose identifies subgroups with differing metabolic profiles and β-cell function. These findings highlight substantial metabolic heterogeneity within this population. However, given the cross-sectional design of the study, longitudinal investigations are required to determine whether these metabolic differences translate into differences in future diabetes risk and clinical outcomes. Not applicable.

PMID 43052968
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多insulin human + insulin isophane